1. AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france). (15th June 2017) Authors: Soubrier, M; Castagné, B; Pereira, B; Fan, A; Frayssac, T; Couderc, M; Malochet-Guinamand, S; Mathieu, S; Tatar, Z; Tournadre, A; Dubost, J-J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗